Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05438368 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GD2/CD70 Bi-specific CAR-T Cell Therapy

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Dec 31, 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v3
  2. Primary completion date: Dec 31, 2025 to Dec 31, 2029
    • Start date changed from estimate of Jun 30, 2022 to Jun 1, 2026
    • Study completion date: Jun 30, 2026 to Dec 31, 2030
    • Site contact updated
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the feasibility, safety and efficacy of GD2/CD70 bi-specific CAR-T cell therapy in patients with GD2 and/or CD70 positive tumor. Another goal of the study is to learn more about the function of the GD2/CD70 bi-specific CAR-T cells and their persistency in patients.
Trial Details
NCT Number NCT05438368
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Cancer Disease
Related terms Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov